ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2027 • ACR Convergence 2022

    Labial and Parotid Salivary Gland Histopathology in Primary Sjögren’s Syndrome

    Uzma Nakshbandi1, Martha S. van Ginkel1, Silvia Liefers2, Hendrika Bootsma2, Fred Spijkervet2, Arjan Vissink1, Bert van der Vegt1 and Frans Kroese2, 1University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 2University Medical Center Groningen, Groningen, Netherlands

    Background/Purpose: Salivary gland involvement is a hallmark of disease in primary Sjögren's syndrome (pSS). This is reflected by the prominent role of a positive biopsy…
  • Abstract Number: 2016 • ACR Convergence 2022

    Safety and Efficacy Associated with Long-Term Low Dose Glucocorticoids in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials

    Andriko Palmowski1, Sabrina Mai Nielsen2, Zhivana Boyadzhieva3, Abelina Schneider3, Anne Pankow3, Linda Hartman4, Jose Pereira da Silva5, John Kirwan6, Siegfried Wassenberg7, Christian Dejaco8, Robin Christensen9, Maarten Boers10 and Frank Buttgereit11, 1Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 2The Parker Institute, Section for Biostatistics and Evidence-Based Research, Bispebjerg-Frederiksberg Hospital, Frederiksberg, Denmark, 3Charité-Universitätsmedizin Berlin, Berlin, Germany, 4Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam, Netherlands, 5University of Coimbra, Rheumatology, Columbia, Portugal, 6University of Bristol, Bristol, United Kingdom, 7Rheumazentrum Ratingen, Ratingen, Germany, 8Department of Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy, and Department of Rheumatology and Immunology, Medical University of Graz, Graz, Austria, 9Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, 10Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, 11Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany

    Background/Purpose: There is ongoing controversy about the safety and efficacy of long-term low dose glucocorticoids (GCs) in rheumatoid arthritis (RA). Our aim was to study…
  • Abstract Number: 2022 • ACR Convergence 2022

    Outcome of Pregnancy in Women with Primary Sjögren’s Syndrome Compared to the General Population: The French Multicenter Prospective GR2 Study

    Gregoire Martin de Fremont1, Nathalie Costedoat-Chalumeau2, Rakiba Belkhir3, Gaelle Guettrot-Imbert4, Nathalie Morel4, Gaetane Nocturne5, Anna Molto6, Tiphaine Goulenok7, Elisabeth Diot8, Estibaliz Lazaro9, Laurent Perard10, Nicole Ferreira11, Maelle Le Besnerais12, Nicolas Limal7, Nihal Martis13, Noémie Abisror14, Odile Debouverie15, Christophe Richez16, Vincent Sobanski17, Francois Maurier18, Gaetan Sauvetre12, Herve Levesque12, Marie Agnes Timsit19, Nathalie Tieule13, Pauline Orquevaux20, GEFA Collaborative group21, Matthieu Mahevas22, Celine Lartigau Roussin23, Elodie Chauvet24, Emilie Berthoux25, Francoise Sarrot Reynauld26, Loic Raffray27, Marion Couderc28, Nicolas Martin Silva29, Noemie Jourde Chiche30, Nicolas Belhomme31, Thierry Thomas32, Vincent Poindron33, Viviane Queyrel13, Juliette Delforge34, Camille Le Ray35, Emmanuelle Pannier35, Xavier Mariette36, Veronique Le Guern4 and Raphaèle Seror37, 1Rheumatology department, Kremlin Bicêtre hospital, APHP, Paris, France, 2Inserm DR Paris 5, Paris, France, 3Rheumatology departement, Bicêtre, Paris-Saclay university, Le Kremlin Bicêtre, France, 4Hôpital Cochin, Paris, France, 5APHP, Le Kremlin Bicêtre, France, 6Rheumatology Department, Cochin Hospital, APHP, Paris, France, 7APHP, Paris, France, 8CHU Tours, Tours, France, 9Bordeaux Hospital University, Bordeaux, France, 10CHU Lyon, Lyon, France, 11department of Internal Medecine, CHU de Tours, Tours, France, 12CHU Rouen, Rouen, France, 13CHU Nice, Nice, France, 14Hopital Saint Antoine, Paris, France, 15CHU Poitiers, Poitiers, France, 16Université de Bordeaux, Bordeaux, France, 17Université de Lille, Lille, France, 18Hôpitaux privés de Metz, Metz, France, 19CHU Brest, Brest, France, 20CHU Reims, Reims, France, 21Saint Joseph Hospital, Marseille, France, 22CHU Mondor, Creteil, France, 23CH La Réunion, CH la Réunion, France, 24CH Cabestany, Cabestany, France, 25CH Saint Joseph Saint Luc, Lyon, France, 26CHU Grenoble, CHU Grenoble, France, 27CH St Denis Reunion, Saint Denis Reunion, France, 28University Hospital, Clermont-Ferrand, France, 29CHU Caen, Caen, France, 30APHM, Marseille, France, 31CHU Rennes, Rennes, France, 32CHU Saint Etienne, Saint Etienne, France, 33Immunologie clinique et médecine interne, Hôpitaux universitaires de Strasbourg, Strasbourg, France, 34Jean Verfier, Bobigny, France, 35Port Royal, Paris, France, 36Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, 37University Hospital Paris-Saclay, Le Kremlin Bicêtre, France

    Background/Purpose: In the context of primary Sjögren's syndrome (pSS), only a few retrospective studies using heterogeneous methods have investigated the risk of adverse pregnancy outcomes…
  • Abstract Number: 2026 • ACR Convergence 2022

    Serum and Tear Autoantibodies from nor Mice as Potential Diagnostic Indicators of Local and Systemic Inflammation in Sjögren’s Syndrome

    Shruti Singh Kakan1, Yaping Ju2, Maria Edman2 and Sarah Hamm-Alvarez3, 1Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California; Department of Ophthalmology, Keck School of Medicine, Roski Eye Institute, University of Southern California, Los Angeles, CA, 2Department of Ophthalmology, Keck School of Medicine, Roski Eye Institute, University of Southern California, Los Angeles, CA, 3Department of Ophthalmology, Keck School of Medicine, Roski Eye Institute, University of Southern California; Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA

    Background/Purpose: Sjögren's Syndrome (SS) is an autoimmune disease characterized by infiltration of lymphocytes into lacrimal (LG) and salivary (SG) glands and their concurrent loss of…
  • Abstract Number: 2028 • ACR Convergence 2022

    The Value of FDG-PET/CT in the Detection of Lymphomas Associated with Primary Sjögren’s Syndrome

    Martha S. van Ginkel1, Andor WJM Glaudemans1, Bert van der Vegt1, Arjan Vissink1, Frans Kroese2 and Hendrika Bootsma2, 1University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 2University Medical Center Groningen, Groningen, Netherlands

    Background/Purpose: Primary Sjögren's syndrome (pSS) patients have an increased risk of developing a lymphoma. PSS-associated lymphomas are mostly of the mucosa associated lymphoid tissue (MALT)…
  • Abstract Number: 1983 • ACR Convergence 2022

    Anti-S1 Antibody Levels Two Weeks After the Second Dose of an mRNA anti-SARS-CoV2 Vaccine Predict Maintenance of a Potent Neutralizing Activity over 24 Weeks in RA Patients

    Kristin Schmiedeberg1, Irene Abela2, Nicolas Vuilleumier3, Johannes von Kempis4 and Andrea Rubbert-Roth5, 1Cantonal Hospital St Gallen, St.Gallen, Switzerland, 2Institute of Medical Virology, University of Zurich, Zürich, Switzerland, 3Laboratory Medicine Division, Geneva University Hospitals, Geneva, Switzerland, 4Division of Rheumatology, Cantonal Hospital St.Gallen, St. Gallen, Switzerland, 5Division of Rheumatology, Cantonal Clinic St Gallen, St.Gallen, Switzerland

    Background/Purpose: Patients with inflammatory rheumatic diseases (IRD) on immunomodulatory therapies have a higher likelihood of an impaired vaccine-induced immune response following an mRNA anti-SARS-CoV-2 vaccine.…
  • Abstract Number: 1982 • ACR Convergence 2022

    Pluripotency Marker PBX1 Predicts Treatment Effect in Rheumatoid Arthritis

    Karin Andersson1, Eric Malmhäll-Bah2, Nina Oparina1, Tao Weiyang3, Malin Erlandsson1, Venkataragavan Chandrasekaran2, Aridaman Pandit3, Sofia Töyrä Silfverswärd4, Maria Bokarewa4 and Rille pullerits4, 1Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden, 2Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 3Center for Translational Immunology, University Medical Center, Utrecht, Netherlands, 4Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden

    Background/Purpose: Self-renewal ability, which is important for the adaptive immunity and adequate T cell function, is severely impaired in rheumatoid arthritis (RA). This leads to…
  • Abstract Number: 2014 • ACR Convergence 2022

    Difficult to Treat Rheumatoid Arthritis: Prevalence of Different Objective Patterns, Predictive Characteristics, and Associated Factors in 1-Year Follow-Up

    Einer Sanchez-Prado, ronald Perez, Laura Cuellar, jonatan mareco, Santiago Ruta, Sebastian Magri and Rodrigo Garcia Salinas, Hospital Italiano de La Plata, La Plata, Argentina

    Background/Purpose: Difficult-to-Treat Rheumatoid Arthritis (RA) (D2T), is a concept recently defined by EULAR, it refers to patients who do not achieve the therapeutic target, who…
  • Abstract Number: 1981 • ACR Convergence 2022

    Rho-GTPase Expression Recruits CD14+ Cells to Joints in Rheumatoid Arthritis and Predicts Good Response to JAK-inhibitor Treatment

    Eric Malmhäll-Bah1, Karin Andersson2, Nina Oparina2, Sofia Töyrä Silfverswärd3, Malin Erlandsson2 and Maria Bokarewa3, 1Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 2Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden, 3Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden

    Background/Purpose: While examining arthritis development in GGTaseI-deficient mice, we found that hyperactive Rho-GTPases regulate the thymic egress of CD4+ T cells to the peripheral lymphoid…
  • Abstract Number: 1440 • ACR Convergence 2022

    Interrelation of T-cell Cytokines and Autoantibodies in Lupus Nephritis: A Cross-sectional Study

    Fatima Alduraibi1, Kathryn Sullivan1, Winn Walter Chatham2, Hui-Chen Hsu1 and John Mountz1, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Clinical Immunology and Rheumatology, Birmingham, AL

    Background/Purpose: To determine if different classes of lupus nephritis (LN) are correlated with specific circulating autoantibodies (autoAbs) and T-helper cell cytokines and other manifestations of…
  • Abstract Number: 1446 • ACR Convergence 2022

    Contrast Enhaced Articular Magnetic Resonance Imaging (MRI) and Health Related Quality of Life in SLE Patients

    Tarek Carlos Salman-Monte1, Patricia Corzo2, Ivan Garcia-Duitama3, ANA Agustí Claramunt3, Irene Carrion Barbera4, Salvatore Marsico3 and Jordi Monfort5, 1Hospital del Mar/Parc de Salut Mar-IMIM/UEC-AIS, Barcelona, Spain, 2Hospital Clínic de Barcelona, Barcelona, Spain, 3Hospital del Mar, Radiology, Barcelona, Spain, 4Hospital del Mar, Rheumatology, Barcelona, Spain, 5Hospital del Mar, Barcelona, Spain

    Background/Purpose: Joint involvement in SLE is the most frequent manifestation and shows a wide heterogeneity (1) . It has not a valid classification and it…
  • Abstract Number: 1978 • ACR Convergence 2022

    Using Administrative Health Data to Construct a Frailty Index as a Measure of Susceptibility to Adverse Health Outcomes Among Individuals with Rheumatoid Arthritis

    Alexandra Legge1 and Diane Lacaille2, 1Arthritis Research Canada, Dalhousie University, Halifax, NS, Canada, 2Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: Frailty is increasingly recognized among individuals living with RA. While several tools are available to assess frailty in clinical settings, it is less readily…
  • Abstract Number: 2021 • ACR Convergence 2022

    Early Histopathological Changes of the Salivary Glands Associated with the Development of Primary Sjögren’s Syndrome

    Xiaomei Shan1, Clara Reichardt1, Jeeshan Singh1, Anne Zeitler2, Christine Schauer1, Jasmin Knopf1, Martin Herrmann1, Gerhard Grossmayer1, Georg Schett1 and Luis Munoz1, 1Universitätsklinikum Erlangen, Erlangen, Germany, 2Friedrich-Alexander University Erlangen Nürnberg, Erlangen, Germany

    Background/Purpose: Primary Sjögren's syndrome (PSS) is a chronic inflammatory disease affecting exocrine glands including salivary and lacrimal glands that leads to dry eyes and mouth…
  • Abstract Number: 1989 • ACR Convergence 2022

    Predictors of Flare in the RHEUmatoid Arthritis Medication TAPering (RHEUMTAP) Cohort

    Nada Alrifai1, Mohamed Tageldin2, Malavikalakshmi Attur2, Nicholas Wilson2, Rebecca schorr2 and Tarun Sharma2, 1Allegheny Health Network, Pittsburgh, 2Allegheny Health Network, Pittsburgh, PA

    Background/Purpose: Long term use of conventional synthetic DMARDs (csDMARDs) and biologics in RA has clinical risks including infection and malignancy. Few RCTs and real-world studies…
  • Abstract Number: 1438 • ACR Convergence 2022

    The Ratio Between Biological and Glucocorticoid Use in Different Countries Worldwide: Results from the METEOR Registry

    Isabell Nevins1, CF Allaart1, David Vega Morales2, Lai Ling Winchow3, Arvind Chopra4, Ana Maria Rodrigues5, Tom Huizinga1, Maarten Boers6 and Sytske Anne Bergstra7, 1Leiden University Medical Center, Leiden, Netherlands, 2Autonomous University of Nuevo León, Monterrey, Mexico, 3Chris hani baragwanath academic hospital, Johannesburg, South Africa, 4Center for Rheumatic Diseases, Pune, Maharashtra, India, 5Reuma.pt, Sociedade Portuguesa de Reumatologia, Lisbon, Portugal, 6Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, 7LUMC, Leiden, Netherlands

    Background/Purpose: Previous studies have demonstrated differing bDMARD prescription rates between countries, which seems to be amongst others related to a country's socioeconomic status. In contrast,…
  • « Previous Page
  • 1
  • …
  • 449
  • 450
  • 451
  • 452
  • 453
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology